checkout $mikp

$LUSI, $HBRM, $SAMP: Heating up

MHYS huge Sony news will still send this running

$DSCR: Qiaopai, New hemp food processor from China

$GEGP, $DKGR, $DBMM, $SRGL, $NOHO: 1s lotto

$DSCR: Building with Hempcrete

$DSCR: Chart & DD:



http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109877969



- Go DSCR

$DSCR: Hemp oil extract CBD being promoted as alternative health treatment for cancer, epilepsy

ENRT CHANGING IT UP HERE......Hammer
"Times Have Changed So Have We" Enertopia Corp. (OTCBB: ENRT)

Enertopia Targets Canadian Medical Marijuana Business

$DSCR: Hemp oil extract CBD being promoted as alternative health treatment for cancer, epilepsy

$IDGC: 3s

$DSCR: Discovery Minerals Engages In Joint Venture Discussions with Florida Dispensary Candidate
Date : 05/06/2014 @ 8:30AM
Source : PR Newswire (US)
Stock : Discovery Minerals Ltd. (PC) (DSCR)


Discovery Minerals LTD. (OTC PINK: DSCR) (PINKSHEETS: DSCR) is currently in discussions with an established Florida nursery who meets the stringent application requirements of the recently passed Compassionate Medical Cannabis Act of 2014. In the event a license is granted, the dispensing organization will be responsible for the cultivation, processing, and dispensing of the low-THC Cannabis strain known as Charlotte's Web.

Announced May 1st, 2014, the newly passed Act in Florida requires certain specific criteria to qualify for the very limited number of available licenses; the nature of the requirements has reduced the number of possible applicants to approximately 35 entities. These applicants must be able to demonstrate a valid certificate of registration issued by Florida's Department of Agriculture and Consumer Services with 30 years of continuous operations. The full Act can be read by clicking this link:

www.flsenate.gov/Session/Bill/2014/1030/BillText/er/PDF

The potential Joint Venture between Discovery and the Nursery Partner will access a vertically integrated business network to conform to the law's proposed requirements.

About Discovery Minerals LTD.:

Discovery Minerals Ltd., (OTC: DSCR) is a production stage company formed to acquire and develop natural resource properties. Activities include gold, precious metals and petroleum minerals, including rare earth minerals production and sales. The Company initiated a new program to evaluate undervalued assets, including clean tech and alternative energy investments, for potential addition to its portfolio.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Person:
Bill McNerney
+1-310-961-4654
At: info@discoveryholdingscorp.com


- Go DSCR

BABL NOW GOING GREEN.......5 days in a ROW......Hammer

BOY IS BABL GOING OFF ON THE SOCIAL MEDIA SITES......SEEN LIKE 40+++++++ TWEETS........Hammer

CPE near 52 week higs ~

RVDO HERE.......GREAT NEWS LINKS....... http://www.otcmarkets.com/stock/RVDO/news - http://finance.yahoo.com/q/h?s=RVDO+Headlines

CLSN on fire!! check here -->
http://profit.ly/1MoBI4

CPE videochart

CPE closed today at hod

IN CPE @ 6.45

775

Valeant Pharmaceuticals

One specialty pharmaceutical player that insiders are loading up on here is Valeant Pharmaceuticals (VRX), which develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Insiders are buying this stock into massive strength, since shares are up sharply in 2013 by 86%.

>>4 Stocks Rising on Unusual Volume

Valeant Pharmaceuticals has a market cap of $37 billion and an enterprise value of $53 billion. This stock trades at a fair valuation, with a price-to-sales of 7.78 and a price-to-book of 7.35. This is not a cash-rich company, since the total cash position on its balance sheet is $596.35 million and its total debt is a whopping $17.40 billion.

The CEO just bought 184,247 shares, or about $14.99 million worth of stock, at $81.41 per share.

From a technical perspective, VRX is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock is starting to bounce higher right above its 50-day moving average of $108.87 a share. That bounce is quickly pushing shares of VRX within range of triggering a near-term breakout trade.

If you're bullish on VRX, then I would look for long-biased trades as long as this stock is trending above its 50-day at $108.87 or above more near-term support at $105.17 and then once breaks out above some near-term overhead resistance levels at $112.40 to $112.47 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.13 million shares. If that breakout hits soon, then VRX will set up to re-test or possibly take out its next major overhead resistance levels at $115 to its 52-week high at $115.40 a share. Any high-volume move above $115.40 will then give VRX a chance to tag of trend north of $120 a share.

Office Depot

Another name that insiders are very active in here is Office Depot (ODP), which is a global supplier of office products and services under the Office Depot brand and other proprietary brand names. Insiders are buying this stock into notable strength, since shares have risen 59% so far in 2013.

>>5 Rocket Stocks Worth Buying This Week

Office Depot has a market cap of $1.5 billion and an enterprise value of $1.2 billion. This stock trades at a fair valuation, with a trailing price-to-earnings of 43.78 and a forward price-to-earnings of 20.04. Its estimated growth rate for this year is -33.3%, and for next year it's pegged at 1,200%. This is a cash-rich company, since the total cash position on its balance sheet is $724.74 million and its total debt is $495.17 million.

A director just bought 1,350,000 shares, or about $7.04 million worth of stock, at $5.21 per share.

From a technical perspective, ODP is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock has been trending sideways for the last month and change, with shares moving between $4.83 on the downside and $5.85 on the upside. Traders should now look for any high-volume move above the upper-end of its recent range since that could trigger a big breakout trade for shares of ODP.

If you're in the bull camp on ODP, then I would look for long-biased trades as long as this stock is trending above some near-term support at $5.07 or above more support at $4.83 and then once it breaks out above some near-term overhead resistance levels at $5.65 to $5.85 a share, and then above its 52-week high at $6.10 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 11.07 million shares. If that breakout triggers soon, then ODP will set up to enter new 52-week-high territory above $6.10, which is bullish technical price action. Some possible upside targets off that move are $7 to $8 a share.

Horizon Pharma

One bio therapeutic drugs player that insiders are snapping up a large amount of stock in here is Horizon Pharma (HZNP) is a specialty pharmaceutical company that, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain and inflammatory diseases. Insiders are buying this stock into significant strength, since shares are up huge so far in 2013 by 192%.

>>5 Stocks Ready to Break Out

Horizon Pharma has a market cap of $448 million and an enterprise value of $434 million. This stock trades at a premium valuation, with a forward price-to-earnings of 84.25. Its estimated growth rate for this year is 62.4%, and for next year it's pegged at 109.4%. This is just barely a cash-rich company, since the total cash position on its balance sheet is $58.65 million and its total debt is $45.58 million.

A director just bought 668,673 shares, or about $4.34 million worth of stock, at $6.50 per share.

From a technical perspective, HZNP is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last three months and change, with shares moving higher from its low of $2.11 to its recent high of $7.39 a share. During that uptrend, shares of HZNP have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of HZNP within range of triggering a big breakout trade.

If you're bullish on HZNP, then I would look for long-biased trades as long as this stock is trending above some key near-term support levels at $6.64 or at $6, then once it breaks out above some near-term overhead resistance levels at $6.84 to $7.15 a share and then above its 52-week high at $7.39 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 1.27 million shares. If that breakout hits soon, then HZNP will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are its next major overhead resistance levels at $8.72 to $9. Any high-volume move above $9 will then give HZNP a chance to tag or trend north of $10 a share.

Nuance Communications

One technology player that insiders are jumping into large here is Nuance Communications (NUAN), which offers voice and language solutions for healthcare, mobile, consumer, enterprise customer service, and imaging markets. Insiders are buying this stock into significant weakness, since shares are down by 33%.

>>4 Tech Stocks Under $10 to Watch

Nuance Communications has a market cap of $4.6 billion and an enterprise value of $7.4 billion. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 31.40 and a forward price-to-earnings of 10.29. Its estimated growth rate for this year is -18.8%, and for next year it's pegged at 12%. This is not a cash-rich company, since the total cash position on its balance sheet is $1.01 billion and its total debt is $2.34 billion.

A beneficial owner just bought 423,400 shares, or about $5.97 million worth of stock, at $14.12 to $14.20 per share.

From a technical perspective, NUAN is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been uptrending since gapping down sharply few weeks ago, with shares moving higher from its low of $13 to its intraday high of $14.93 a share. During that uptrend, shares of NUAN have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of NUAN within range of triggering a major breakout trade.

If you're bullish on NUAN, then I would look for long-biased trades as long as this stock is trending above some key near-term support levels at $14 or at $13.50, and then once it takes out its gap down day high of $14.91 a share high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 6.82 million shares. If that breakout hits soon, then NUAN will set up to re-fill some of its previous gap down zone that started near $16.50 a share. Any high-volume move above $16.50 will then give NUAN a chance to tag $18 to its 200-day moving average at $18.44 a share.

Esterline Technologies

One final name with some big insider buying is Esterline Technologies (ESL), which designs, manufactures and markets highly engineered products for the aerospace and defense sectors. Insiders are buying this stock into big time strength, since shares are up sharply by 51% so far in 2013.

>>The Truth About Amazon's Drones

Esterline Technologies has a market cap of $3 billion and an enterprise value of $3.2 billion. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 18.84 and a forward price-to-earnings of 15.14. Its estimated growth rate for this year is -0.40%, and for next year it's pegged at 12.5%. This is not a cash-rich company, since the total cash position on its balance sheet is $199.25 million and its total debt is $754.49 million.

A director just bought 103,528 shares, or about $9.50 million worth of stock, at $91.55 to $92.51 per share.

From a technical perspective, ESL is currently trending well above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last two months, with shares soaring higher from its low of $78.17 to its intraday high of $96.81 a share.

During that uptrend, shares of ESL have been consistently making higher lows and higher highs, which is bullish technical price action. That said, shares of ESL have now started to enter overbought territory, since its current relative strength index reading is 79.91. Overbought can always get more overbought, but it's also an area that can be dangerous to enter a stock from the long side.

If you're bullish on ESL, then I would look to get long this strong trending stock after it works off some of its current overbought condition. Look for a sharp pullback in shares of ESL that bring the stock down towards some key near-term support levels around the $87.50 area, or near its 50-day moving average of $83.78 a share. If ESL doesn't pullback significantly, then traders can look to go long this stock once it clears and closes above its new 52-week high at $96.81 a share with strong volume.

To see more stocks with notable insider buying, check out the Stocks With Big Insider Buying portfolio on

Max Keiser Discusses QE & Rigged Global Markets -

30 Min. says TCEL BOUNCE IS COMING........Hammer

CPE

http://stockcharts.com/c-sc/sc?s=cpe&p=D&b=5&g=0&i=t67626106445&r=1365625889736

DNDN ready

lsg

FNRC NEWS LINK.....Hammer

http://ih.advfn.com/p.php?pid=nmona&article=54769546

TLON on watch here undervalue

GOK

CAHI and SNTL are 2 solid plays that I am accumulating.

I have DD sheets for Madison Square Garden (big board)
and for APDN my favorite, a pink. What would you guys like.
tomorrow.

Baggers thanks you

Hi Cube. Looking in. B'marked.

VNDB setting up for a bounce imo.

Thanks Baggers...will take a look.

TLON could be ready undervalue -->

Marked the board.

HUSA

AUMN shareholder fact sheet shows 60M ounces of silver, and an additional 60M ounces found in an infrared scan. Total of 120M ounces of Silver which = 3.4B. Current Market Cap = $261M.

http://www.goldenminerals.com/pdfs/GLDN_InvestorKit/Golden-Minerals-Fact-Sheet-Sept-2012.pdf

CADX

MNKD

RSH

OTT

NBS

nokia

zz

XOMA Receives Orphan Drug Designation From U.S. Food & Drug Administration for Gevokizumab


Today : Wednesday 22 August 2012
Click Here for more Xoma Charts.

XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that gevokizumab, the company's IL-1 beta modulating antibody, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.

The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. In fulfilling that task, OOPD evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare disease and to further advance scientific development of such promising medical products. The office also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.

About Gevokizumab

Gevokizumab (XOMA 052) is a potent monoclonal antibody with unique allosteric modulating properties and the potential to treat patients with a wide variety of inflammatory diseases and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine that has been shown to be involved in Behcet's and other forms of non-infectious uveitis, cardiovascular disease, and other auto-inflammatory diseases. In binding to IL-1 beta, gevokizumab inhibits the activation of the IL-1 receptor, thereby modulating the cellular signaling events that produce inflammation.

Servier is XOMA's development and commercialization partner for gevokizumab. XOMA holds rights to gevokizumab in the U.S. and Japan for non-cardiometabolic indications, including non-infectious uveitis, acne, and erosive osteoarthritis of the hand for which clinical studies are ongoing. Information on all gevokizumab clinical studies can be found at www.clinicaltrials.gov.

About Non-infectious Uveitis

The term uveitis broadly refers to the inflammatory diseases that affect the portion of the eye known as the uvea, which is the middle of three layers that surround the eye. People with uveitis may experience decreased vision, pain, light sensitivity, and floaters. Uveitis may be caused by an infection that is commonly treated with an antimicrobial agent, or by an unknown pathogen triggering inflammation, called non-infectious uveitis.

The most common form of uveitis affects the front of the uvea and is known as anterior uveitis. Other forms include intermediate uveitis, posterior uveitis, and pan uveitis. These types differ in that they all include involvement of the back portions of the uvea. Posterior uveitis refers to inflammation in the retina and the choroid, and it may result from a different immune response trigger. Pan-uveitis refers to inflammation of all three major parts of the eye. Behcet's uveitis is a well-known form of pan-uveitis. Due to the swelling of tissues critical to vision, intermediate, posterior, and pan-uveitis (which collectively make up NIU) can lead to blindness if not treated.

About XOMA Corporation

XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (Servier) through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes. In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier's ACEON® (perindopril erbumine) and a patent-protected portfolio of product candidates.

More detailed information can be found at www.xoma.com.

The XOMA Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960

CONTACT: XOMA Corporation

Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com

Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com

Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com

Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Amp...
Print
Alert

Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the "FDA"). At that meeting, the FDA agreed to accept, for review, new analyses of data from Hemispherx's AMP-516 Phase III Clinical Trial ("AMP-516 Trial") in support of its New Drug Application ("NDA") for Ampligen® (Poly I : Poly C12U). If found sufficient to support approval of the drug, these new analyses will be in lieu of an additional confirmatory Phase III study called for in the Agency's November 25, 2009, Complete Response Letter ("CRL"). The FDA has advised that whether the new analyses provide adequate evidence of Ampligen®'s efficacy in treating Chronic Fatigue Syndrome ("CFS") will ultimately be a review issue.

In its CRL, the FDA recommended at least one additional clinical study of Ampligen® in CFS patients, including at least 300 patients on dose regimens intended for marketing. In November 2010, Hemispherx announced the publication of new analyses of data from the AMP-516 Trial showing that patients on Ampligen® reduced their use of concomitant medications compared to patients receiving placebo. In particular, Ampligen® patients reduced their use of medications which may prolong the QT interval. Prolongation of the QT interval is a known risk factor for sudden cardiac death and arrhythmias. A greater portion of the placebo patients were found to have a significant prolongation of the QT interval compared to patients who had received Ampligen®, thereby creating a cardiac risk situation in the CFS patients. Cardiac death is one of three major causes of premature death in CFS, which affects predominantly women in their 40s. The article can be found at http://jrnlappliedresearch.com/articles/Vol10Iss3/Vol10%20Iss3Stouch.pdf. At present, no drug has received FDA approval to treat this chronic, seriously debilitating disease.

In March, 2012, a new peer reviewed analysis of data from the AMP-516 Trial was published showing that the proportions of Ampligen® patients with exercise improvements of at least 25% and at least 50% were, respectively, 1.7 and 1.9-fold greater than those patients on placebo. A continuous responder analysis, which examined response improvements from 25% to 50% in 5% increments, showed a greater improvement in exercise tolerance for patients receiving Ampligen® versus placebo at every 5% increment above 25%. The article can be found at http://dx.plos.org/10.1371/journal.pone.0031334.

On June 8, 2012, the Company and its consultants met with the FDA to discuss certain aspects of the CRL relating to its NDA for Ampligen® for the treatment of severely debilitated patients with CFS. At this time, the Company believes the key points from the meeting to be undertaken by the Company in conjunction with its complete response include the following:

The FDA agreed to accept, for review, in Hemispherx's complete response new analyses of data from the AMP-516 Trial. Whether these data provide adequate evidence of efficacy will ultimately be a review issue, and there can be no assurance the FDA will conclude the data are adequate to support approval of the Ampligen® NDA.
As the product is a new molecular entity, the FDA anticipates that the data submitted in the NDA would be presented at a public FDA Advisory Committee meeting.
The FDA requires that the Company's complete response include all information necessary for review at the time of filing and that it address all deficiencies identified in the CRL.
Hemispherx's New Brunswick manufacturing facility would be expected to be ready for GMP pre-approval inspection at the time of the complete response.
Hemispherx will include in the complete response a request for postponement of rodent carcinogenicity study requirements and a justification for this request.

Hemispherx plans to submit the complete response in the 3rd quarter 2012. The FDA has advised that, once submitted, the complete response will be on a six month review cycle at the FDA. The FDA's agreement to review the complete response does not commit the Agency to approve the Ampligen® NDA. Further, although the proposed New Brunswick manufacturing facility already has received a Biologics License from the FDA for its commercial product, Alferon N Injection®, no guarantee can be made at this time that the facility will necessarily pass a pre-approval inspection for Ampligen® manufacture, which is conducted in a separately dedicated area within the overall New Brunswick manufacturing complex.

As a result of the meeting, Hemispherx has accelerated its preparedness for FDA pre-approval inspections by hiring additional staff, consultants, and various independent contractors.

DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking" statements (explained below), including statements about the remaining steps to potentially gain FDA approval of the Ampligen® NDA for the treatment of Chronic Fatigue Syndrome. The final results of these and other ongoing activities could vary materially from Hemispherx's expectations and could adversely affect the chances for approval of the Ampligen® NDA. These activities and the ultimate outcomes are subject to a variety of risks and uncertainties, including but not limited to risks that (i) the complete response Hemispherx ultimately submits in support of the Ampligen® NDA may not be accepted by the FDA or such acceptance may be delayed; (ii) the FDA may ask for additional data, information or studies to be completed or provided prior to approval; (iii) the FDA may require additional work related to the commercial manufacturing process to be completed prior to approval or may, in the course of the inspection of manufacturing facilities, identify issues to be resolved; and (iv) the FDA may determine that the complete response ultimately submitted by Hemispherx is not "complete," potentially requiring the Company to conduct additional activities before it can re-file, if at all, the complete response. Any failure to satisfy the FDA's requirements could significantly delay, or preclude outright, approval of the Ampligen® NDA.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Because both Ampligen® and Alferon LDO® are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "believes," "plans," "anticipates," and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations and represent the Company's judgment as of the date of this release. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.

CONTACT: Company/Investor Contact:
Dianne Will
Hemispherx Biopharma, Inc.
518-398-6222
ir@hemispherx.net

VG

thank you